Treatment | Fluoxetine | cognitive function | physiological function | healthspan biomarkers | lifespan | Transcriptome | Proteome | Metabolome | Target | Reference | blinded |
CID (PubChem) | 3386 | ChEMBL | | | | | mechanical sensory / touch response | | | | heat stress resistance | | | | quantity of β-Amyloid | | | | translocation of DAF-16 to nucleus | | | | mean lifespan | | | | | | | | | |
Concentration | Exposure time | Food | Growth medium | Special additives | C. elegans strain | Temperature | Change compared to control | Percentual change compared to control | p < 0.05 | notes | Change compared to control | Percentual change compared to control | p < 0.05 | notes | Change compared to control | Percentual change compared to control | p < 0.05 | notes | Change compared to control | Percentual change compared to control | p < 0.05 | notes | Change compared to control | Percentual change compared to control | p < 0.05 | notes | | | | | | |
1 µM | whole life; start: egg stage | OP50 | NGM agar | | CL2006 {dvIs2 [pCL12(unc-54/human Abeta peptide 1-42 minigene) + pRF4]} | 20°C | none | | | paralysis assay with daily measurements of Alzheimer disease model | | | | | | | | | | | | | | | | | | | | | Keowkase R, Aboukhatwa M, Luo Y (2010) Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans. Neuropharmacology 59, 358-365. | |
10 µM | whole life; start: egg stage | OP50 | NGM agar | | CL2006 {dvIs2 [pCL12(unc-54/human Abeta peptide 1-42 minigene) + pRF4]} | 20°C | up | | yes | paralysis assay with daily measurements of Alzheimer disease model | | | | | | | | | | | | | none | | | | | | | | Keowkase R, Aboukhatwa M, Luo Y (2010) Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans. Neuropharmacology 59, 358-365. | |
100 µM | whole life; start: egg stage | OP50 | NGM agar | | CL2006 {dvIs2 [pCL12(unc-54/human Abeta peptide 1-42 minigene) + pRF4]} | 20°C | none | | | paralysis assay with daily measurements of Alzheimer disease model | | | | | | | | | | | | | up | | yes | | | | | | Keowkase R, Aboukhatwa M, Luo Y (2010) Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans. Neuropharmacology 59, 358-365. | |
1000 µM | whole life; start: egg stage | OP50 | NGM agar | | CL2006 {dvIs2 [pCL12(unc-54/human Abeta peptide 1-42 minigene) + pRF4]} | 20°C | up | | yes | paralysis assay with daily measurements of Alzheimer disease model | | | | | down | | no | A1; no change of total amyloid beta level | | | | | none | | | | | | | daf-16 & tph-1 | Keowkase R, Aboukhatwa M, Luo Y (2010) Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans. Neuropharmacology 59, 358-365. | |
1000 µM | whole life; start: egg stage | HT115 (DE3) with RNAi-vector against daf-16 | NGM agar | | CL2006 {dvIs2 [pCL12(unc-54/human Abeta peptide 1-42 minigene) + pRF4]} | 20°C | none | | no | paralysis assay with daily measurements of Alzheimer disease model | | | | | | | | | | | | | | | | | | | | | Keowkase R, Aboukhatwa M, Luo Y (2010) Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans. Neuropharmacology 59, 358-365. | |
1000 µM | whole life; start: egg stage | HT115 (DE3) with RNAi-vector against hsf-1 | NGM agar | | CL2006 {dvIs2 [pCL12(unc-54/human Abeta peptide 1-42 minigene) + pRF4]} | 20°C | up | | yes | paralysis assay with daily measurements of Alzheimer disease model | | | | | | | | | | | | | | | | | | | | | Keowkase R, Aboukhatwa M, Luo Y (2010) Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans. Neuropharmacology 59, 358-365. | |
1000 µM | whole life; start: egg stage | HT115 (DE3) with RNAi-vector against tph-1 | NGM agar | | CL2006 {dvIs2 [pCL12(unc-54/human Abeta peptide 1-42 minigene) + pRF4]} | 20°C | none | | no | paralysis assay with daily measurements of Alzheimer disease model | | | | | | | | | | | | | | | | | | | | | Keowkase R, Aboukhatwa M, Luo Y (2010) Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans. Neuropharmacology 59, 358-365. | |
1000 µM | whole life; start: egg stage | OP50 | NGM agar | | TJ356 {zIs356 [daf-16p::daf-16a/b::GFP + rol-6(su1006)]} | 20°C | | | | | | | | | | | | | up | | yes | | | | | | | | | | Keowkase R, Aboukhatwa M, Luo Y (2010) Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans. Neuropharmacology 59, 358-365. | |
1000 µM | whole life; start: egg stage | OP50 | NGM agar | | N2 (wild type) | 20°C | | | | | up | 38.00 | yes | A1; Stressor: 35°C for 7 hours | | | | | | | | | | | | | | | | | Keowkase R, Aboukhatwa M, Luo Y (2010) Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans. Neuropharmacology 59, 358-365. | |
1000 µM | whole life; start: egg stage | OP50 | NGM agar | | unknown strain [daf-16 deletion mutant] | 20°C | | | | | none | | no | A1; Stressor: 35°C for 7 hours | | | | | | | | | | | | | | | | | Keowkase R, Aboukhatwa M, Luo Y (2010) Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans. Neuropharmacology 59, 358-365. | |